NASDAQ:IMTX Immatics (IMTX) Stock Forecast, Price & News $11.71 -0.14 (-1.18%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$11.61▼$11.9250-Day Range$11.31▼$12.6252-Week Range$5.90▼$13.14Volume317,768 shsAverage Volume290,875 shsMarket Capitalization$897.81 millionP/E RatioN/ADividend YieldN/APrice Target$17.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immatics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.9% Upside$17.67 Price TargetShort InterestBearish12.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.32) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector796th out of 962 stocksBiological Products, Except Diagnostic Industry125th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.67, Immatics has a forecasted upside of 50.9% from its current price of $11.71.Amount of Analyst CoverageImmatics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.05% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 3.3 News and Social Media Coverage News SentimentImmatics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Immatics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions53.42% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.32) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immatics (NASDAQ:IMTX) StockImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTX Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comLeerink Partnrs Analysts Boost Earnings Estimates for Immatics (NASDAQ:IMTX)September 21, 2023 | finance.yahoo.comIMTX Oct 2023 10.000 putSeptember 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 11, 2023 | marketwatch.comImmatics shares rise on Moderna cancer collaborationSeptember 11, 2023 | bizjournals.comModerna enters cancer collaboration with Immatics worth $1.8BAugust 27, 2023 | finance.yahoo.comThose who invested in Immatics (NASDAQ:IMTX) three years ago are up 27%August 21, 2023 | msn.comHow Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%August 18, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Immatics (IMTX)September 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 18, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), CVS Health (CVS)August 17, 2023 | msn.comImmatics GAAP EPS of -€0.32, revenue of €22.4MAugust 17, 2023 | markets.businessinsider.comChardan Capital Sticks to Their Buy Rating for Immatics (IMTX)August 17, 2023 | finance.yahoo.comImmatics Announces Second Quarter 2023 Financial Results and Business UpdateAugust 10, 2023 | finance.yahoo.comImmatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsJuly 24, 2023 | seekingalpha.comImmatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203July 24, 2023 | markets.businessinsider.comWhy Immatics Shares Are Rising TodayJuly 24, 2023 | seekingalpha.comImmatics Is Increasingly Becoming InterestingJuly 24, 2023 | msn.comUpcoming Fed Decision, Earnings Fuel Cautiousness, Driving Quiet Premarket Action for US Equity FuturesJuly 24, 2023 | seekingalpha.comImmatics climbs 8% on $35M investment by Bristol Myers SquibbJune 25, 2023 | fool.comImmatics (NASDAQ: IMTX)May 26, 2023 | finance.yahoo.comCompanies Like Immatics (NASDAQ:IMTX) Are In A Position To Invest In GrowthMay 18, 2023 | markets.businessinsider.comImmatics (IMTX) Gets a Buy from Mizuho SecuritiesMay 17, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Immatics (IMTX)May 16, 2023 | finance.yahoo.comImmatics Announces First Quarter 2023 Financial Results and Business UpdateMay 5, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Immatics (IMTX)May 3, 2023 | msn.comImmatics (IMTX) Moves 27.5% Higher: Will This Strength Last?May 2, 2023 | finance.yahoo.comWhat's Going On With Immatics Shares TodaySee More Headlines Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Company Calendar Last Earnings8/17/2023Today9/24/2023Next Earnings (Estimated)11/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.67 High Stock Price Forecast$25.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+50.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$39.53 million Net Margins-93.53% Pretax Margin-97.30% Return on Equity-41.90% Return on Assets-20.21% Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick Ratio2.93 Sales & Book Value Annual Sales$182.13 million Price / Sales4.93 Cash Flow$0.61 per share Price / Cash Flow19.15 Book Value$2.93 per share Price / Book4.00Miscellaneous Outstanding Shares76,670,000Free Float74,141,000Market Cap$897.81 million OptionableNot Optionable Beta0.47 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 48)CEO, MD, Member of Management Board & Exec. Director Comp: $902kDr. Toni Weinschenk Ph.D. (Age 49)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 57)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 46)Chief Operations Officer Dr. Carsten Reinhardt M.D. (Age 56)Ph.D., Chief Devel. Officer Dr. Rainer Kramer Ph.D. (Age 58)Chief Bus. Officer & Site Head Munich Mr. Cedrik M. Britten M.D. (Age 47)Chief Medical Officer Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Edward A. Sturchio J.D. (Age 47)Gen. Counsel & Sec. Ms. Anja Heuer B.Sc.Sr. Director Corp. Communications & Head of CommunicationsMore ExecutivesKey CompetitorsInhibrxNASDAQ:INBXValnevaNASDAQ:VALNAxcella HealthNASDAQ:AXLASana BiotechnologyNASDAQ:SANAKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 300,000 shares on 8/21/2023Ownership: 0.391%Hudson Bay Capital Management LPBought 155,580 shares on 8/15/2023Ownership: 0.483%Goldman Sachs Group Inc.Sold 16,280 shares on 8/15/2023Ownership: 0.086%Lazard Asset Management LLCSold 70,701 shares on 8/15/2023Ownership: 0.025%Citadel Advisors LLCSold 700 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions IMTX Stock - Frequently Asked Questions Should I buy or sell Immatics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks. What is Immatics' stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price targets for Immatics' shares. Their IMTX share price forecasts range from $12.00 to $25.00. On average, they anticipate the company's share price to reach $17.67 in the next year. This suggests a possible upside of 50.9% from the stock's current price. View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts. How have IMTX shares performed in 2023? Immatics' stock was trading at $8.71 at the start of the year. Since then, IMTX shares have increased by 34.4% and is now trading at $11.71. View the best growth stocks for 2023 here. When is Immatics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 16th 2023. View our IMTX earnings forecast. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) released its quarterly earnings results on Thursday, August, 17th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.01. The firm earned $24.33 million during the quarter, compared to analysts' expectations of $18.97 million. Immatics had a negative trailing twelve-month return on equity of 41.90% and a negative net margin of 93.53%. What ETFs hold Immatics' stock? ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX). What is Immatics' stock symbol? Immatics trades on the NASDAQ under the ticker symbol "IMTX." Who are Immatics' major shareholders? Immatics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Rock Springs Capital Management LP (3.31%), 683 Capital Management LLC (1.76%), Woodline Partners LP (1.58%), Artisan Partners Limited Partnership (0.92%), Sphera Funds Management LTD. (0.80%) and Samsara BioCapital LLC (0.52%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immatics' stock price today? One share of IMTX stock can currently be purchased for approximately $11.71. How much money does Immatics make? Immatics (NASDAQ:IMTX) has a market capitalization of $897.81 million and generates $182.13 million in revenue each year. The company earns $39.53 million in net income (profit) each year or ($1.18) on an earnings per share basis. How many employees does Immatics have? The company employs 210 workers across the globe. How can I contact Immatics? Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 4.97072E+12. This page (NASDAQ:IMTX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.